Stocks Health care KURA
NASDAQ · Health careKura Oncology, Inc. (KURA)
Kura Oncology, Inc. brought in $77.2M of revenue over the twelve months to June 30, 2026. It posted a net loss of $296.8M. In fiscal 2025 capital spending exceeded operating cash flow by $70.7M. At June 30, 2026 it held $70.2M in cash against $9.8M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
Key facts about Kura Oncology, Inc.
- Net worth
- Kura Oncology, Inc. has a market value (market cap) of $692.6M at the latest share price, and shareholders' equity of $48.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $67.5M (+25.2% year on year), with a net loss of $278.7M. Over the 12 months to June 30, 2026: revenue $77.2M, net loss $296.8M.
- Cash flow
- In fiscal 2025 operations used $64.1M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 12, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Kura Oncology, Inc.'s next report was expected around November 3, 2026 and is not on file with the SEC yet.
What Kura Oncology, Inc. does
Kura Oncology, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker KURA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $67.5M | -$278.7M | -$3.18 | -$70.7M |
| 2024 | $53.9M | -$174M | -$2.02 | $133.8M |
| 2023 | $0 | -$152.6M | -$2.08 | -$125M |
| 2022 | n/a | -$135.8M | -$2.03 | -$110.7M |
| 2021 | n/a | -$130.5M | -$1.97 | -$105.7M |
| 2020 | n/a | -$89.6M | -$1.69 | -$72M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where KURA ranks in Health care
Latest SEC filings
What Kura Oncology, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 27, 2026Passive stake changed SCHEDULE 13G/A
- September 9, 2026Other event 8-K
- September 8, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 12, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 37% to $20.9M versus the same quarter last year; diluted EPS -$0.77 versus -$0.75.
- August 12, 2026
- July 29, 2026
- June 4, 2026
- June 4, 2026
- May 26, 2026Additional proxy material DEFA14A
Insider trades
What the people running Kura Oncology, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $2.4M and sold $1.7M worth of shares in the last 90 days. Most of the selling (71%) was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 29, 2026 | Powl Brian T.Chief Commercial Officer | Soldpre-planned (10b5-1) | 15,430 | $165.9K |
| September 29, 2026 | Leoni MollieChief Medical Officer | Soldpre-planned (10b5-1) | 28,802 | $309.6K |
| September 29, 2026 | Ford KathleenChief Operating Officer | Soldpre-planned (10b5-1) | 3,668 | $39.4K |
| September 28, 2026 | Powl Brian T.Chief Commercial Officer | Sold | 9,020 | $94.7K |
| September 28, 2026 | Powl Brian T.Chief Commercial Officer | Soldpre-planned (10b5-1) | 8,000 | $84.5K |
| September 28, 2026 | Doyle Thomas JamesSVP, Finance & Accounting | Sold | 4,607 | $48.4K |
| September 28, 2026 | Leoni MollieChief Medical Officer | Sold | 12,448 | $130.7K |
| September 28, 2026 | Ford KathleenChief Operating Officer | Soldpre-planned (10b5-1) | 6,906 | $72.5K |
Who owns KURA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Bvf Partners L P13G, passive with 9 related filers | 9.99% | November 14, 2025 |
| Montanova Capital, LLC13G, passive with 2 related filers | 9.7% | August 14, 2026 |
| BlackRock, Inc.13G, passive | 8.9% | October 27, 2026 |
| Vanguard Capital Management13G, passive | 5.01% | April 30, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 220 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 10,509,233 | +871,702 |
| Montanova Capital, LLC | 8,575,422 | 0 |
| Bvf Inc | 8,445,769 | 0 |
| State Street Corp | 5,329,208 | +817,317 |
| Vanguard Capital Management LLC | 3,916,164 | +130,479 |
| Armistice Capital, LLC | 3,678,000 | -58,000 |
| Aqr Capital Management LLC | 3,126,727 | +1,002,247 |
| Goldman Sachs Group Inc | 2,265,171 | +831,700 |
| Geode Capital Management, LLC | 2,229,958 | +195,682 |
| Alethea Capital Management, LLC | 2,167,938 | +638,569 |
| Prosight Management, LP | 2,021,964 | -1,334,736 |
| Deep Track Capital, LP | 1,978,565 | -664,977 |
| Renaissance Technologies LLC | 1,663,765 | +81,197 |
| Arrowstreet Capital, Limited Partnership | 1,410,275 | new |
| Vanguard Portfolio Management LLC | 1,329,941 | +99,139 |
| Nan Fung Trinity (HK) Ltd | 1,174,880 | +110,000 |
| Qube Research & Technologies Ltd | 1,169,884 | -466,849 |
| Dimensional Fund Advisors LP | 1,169,189 | -256,756 |
| Bank of America Corp | 1,160,921 | -69,210 |
| Morgan Stanley | 1,160,310 | -3,667 |
Insiders
9 insiders reported holding 1,741,290 shares in total, about $13.6M at the last price.
| Holder | Shares |
|---|---|
| Wilson Troy EdwardPresident and CEO, Director | 914,650479,194 held indirectly |
| Bair Teresa BrophyChief Legal Officer | 187,002 |
| Ford KathleenChief Operating Officer | 142,986 |
| Doyle Thomas JamesSVP, Finance & Accounting | 142,428 |
| Leoni MollieChief Medical Officer | 141,095 |
| Powl Brian T.Chief Commercial Officer | 136,819 |
| Burrows FrancisChief Scientific Officer | 42,327 |
| Hasnain FaheemDirector | 23,983 |
| Malley ThomasDirector | 10,000 |
Questions about KURA
What does Kura Oncology, Inc. do?
Kura Oncology, Inc. is a company in the Health care sector, listed on NASDAQ as KURA. Its shares trade on NASDAQ under the ticker KURA.
What is Kura Oncology, Inc.'s net worth?
Kura Oncology, Inc. has a market value (market cap) of $692.6M at the latest share price, and shareholders' equity of $48.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Kura Oncology, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $296.8M on revenue of $77.2M.
How much revenue does Kura Oncology, Inc. make?
Over the twelve months to June 30, 2026 Kura Oncology, Inc. reported revenue of $77.2M.
When did Kura Oncology, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake changed from October 27, 2026.
When is Kura Oncology, Inc.'s next earnings report?
Kura Oncology, Inc.'s next report was expected around November 3, 2026 and is not on file with the SEC yet.
Similar companies
Compare KURA with
Follow KURA
Get an email when Kura Oncology, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Kura Oncology, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.